• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国成年人动脉粥样硬化性心血管疾病的风险分层

Risk stratification of atherosclerotic cardiovascular disease in Chinese adults.

作者信息

Yang Xue-Li, Chen Ji-Chun, Li Jian-Xin, Cao Jie, Lu Xiang-Feng, Liu Fang-Chao, Hu Dong-Sheng, Liu Xiao-Qing, Shen Chong, Yu Ling, Lu Fang-Hong, Wu Xian-Ping, Zhao Lian-Cheng, Huang Jian-Feng, Li Ying, Wu Xi-Gui, Gu Dong-Feng

机构信息

Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

Department of Prevention Medicine, Shenzhen University School of Medicine, Guangdong 518000, China.

出版信息

Chronic Dis Transl Med. 2016 Oct 21;2(2):102-109. doi: 10.1016/j.cdtm.2016.10.001. eCollection 2016 Jun.

DOI:10.1016/j.cdtm.2016.10.001
PMID:29063030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5643596/
Abstract

OBJECTIVE

This study aims to determine the distribution of observed atherosclerotic cardiovascular disease (ASCVD) incidence in contemporary cohorts in China, and to identify cut-off points for ASCVD risk classification based on traditional criteria and new equations developed by Prediction for ASCVD Risk in China (China-PAR).

METHODS

The study populations included cohorts in the China-PAR project, with 34,757 participants eligible for the current analysis. Traditional risk stratification was assessed by using Chinese guidelines on prevention of CVD and hypertension, and 5 risk groups were classified based on these guidelines after slight modification for available risk factors. Kaplan-Meier analysis was conducted to obtain the cumulative incidence of observed ASCVD events for all subjects and sub-groups. The predicted 10-year ASCVD risk was obtained using the China-PAR equations.

RESULTS

A total of 1922 ASCVD events were identified during an average follow-up of 14.1 years. According to the group classification based on traditional risk stratification, the observed 10-year risks for ASCVD were 4.61% (95% confidence interval []: 4.11-5.10%) in the moderate-risk group and 8.74% (95% : 7.82-9.66%) in the high-risk group. Based on the China-PAR equations for risk assessment of ASCVD, those with predicted risks of <5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively.

CONCLUSION

The findings enable development of a simple method for classification of individuals into low-, moderate-, and high-risk groups, based on the China-PAR equations. The method will be useful for self-management and prevention of ASCVD in Chinese adults.

摘要

目的

本研究旨在确定中国当代队列中观察到的动脉粥样硬化性心血管疾病(ASCVD)发病率的分布情况,并根据传统标准和中国动脉粥样硬化性心血管疾病风险预测(China-PAR)开发的新方程确定ASCVD风险分类的切点。

方法

研究人群包括China-PAR项目中的队列,共有34757名参与者符合当前分析的条件。采用中国心血管疾病和高血压预防指南评估传统风险分层,并在对可用风险因素进行轻微修改后,根据这些指南将参与者分为5个风险组。采用Kaplan-Meier分析获得所有受试者和亚组观察到的ASCVD事件的累积发病率。使用China-PAR方程获得预测的10年ASCVD风险。

结果

在平均14.1年的随访期间,共确定了1922例ASCVD事件。根据基于传统风险分层的分组分类,中度风险组观察到的10年ASCVD风险为4.61%(95%置信区间[]:4.11-5.10%),高危组为8.74%(95%:7.82-9.66%)。根据China-PAR ASCVD风险评估方程,预测风险<5%、5-10%和≥10%的患者可分别分为ASCVD低、中、高风险类别。

结论

这些发现有助于基于China-PAR方程开发一种将个体分为低、中、高风险组的简单方法。该方法将有助于中国成年人的ASCVD自我管理和预防。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9038/5643596/80801acb8e7b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9038/5643596/587ee4a6ca1e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9038/5643596/80801acb8e7b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9038/5643596/587ee4a6ca1e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9038/5643596/80801acb8e7b/gr2.jpg

相似文献

1
Risk stratification of atherosclerotic cardiovascular disease in Chinese adults.中国成年人动脉粥样硬化性心血管疾病的风险分层
Chronic Dis Transl Med. 2016 Oct 21;2(2):102-109. doi: 10.1016/j.cdtm.2016.10.001. eCollection 2016 Jun.
2
[Application of the China-PAR risk prediction model for atherosclerotic cardiovascular disease in a rural northern Chinese population].中国-PAR动脉粥样硬化性心血管疾病风险预测模型在中国北方农村人群中的应用
Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Jun 18;49(3):439-445.
3
Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China).预测中国人群动脉粥样硬化性心血管疾病 10 年风险:中国 PAR 项目(中国 ASCVD 风险预测)。
Circulation. 2016 Nov 8;134(19):1430-1440. doi: 10.1161/CIRCULATIONAHA.116.022367. Epub 2016 Sep 28.
4
Ideal cardiovascular health and incidence of atherosclerotic cardiovascular disease among Chinese adults: the China-PAR project.中国成年人理想心血管健康与动脉粥样硬化性心血管疾病发病风险:中国前瞻性研究(China-PAR)。
Sci China Life Sci. 2018 May;61(5):504-514. doi: 10.1007/s11427-018-9281-6. Epub 2018 Mar 19.
5
Evaluation of Atherosclerotic Cardiovascular Risk Prediction Models in China: Results From the CHERRY Study.中国动脉粥样硬化性心血管疾病风险预测模型的评估:CHERRY研究结果
JACC Asia. 2022 Jan 4;2(1):33-43. doi: 10.1016/j.jacasi.2021.10.007. eCollection 2022 Feb.
6
Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.中国北方农村人群动脉粥样硬化性心血管病风险预测模型的表现:来自房山队列研究的结果。
Am Heart J. 2019 May;211:34-44. doi: 10.1016/j.ahj.2019.01.009. Epub 2019 Feb 5.
7
Prediction of 10-year atherosclerotic cardiovascular disease risk among community residents in Shanghai, China - a comparative analysis of risk algorithms.中国上海社区居民 10 年动脉粥样硬化性心血管疾病风险预测-风险算法的比较分析。
Nutr Metab Cardiovasc Dis. 2021 Jun 30;31(7):2058-2067. doi: 10.1016/j.numecd.2021.04.009. Epub 2021 Apr 20.
8
External validation of three atherosclerotic cardiovascular disease risk equations in rural areas of Xinjiang, China.中国新疆农村地区三个动脉粥样硬化性心血管疾病风险方程的外部验证
BMC Public Health. 2020 Sep 29;20(1):1471. doi: 10.1186/s12889-020-09579-4.
9
Predictive value of 10-year atherosclerotic cardiovascular disease risk equations from the China-PAR for new-onset lower extremity peripheral artery disease.中国动脉粥样硬化性心血管病风险评估系统(China-PAR)中10年动脉粥样硬化性心血管病风险方程对新发下肢外周动脉疾病的预测价值
Front Cardiovasc Med. 2022 Oct 4;9:933054. doi: 10.3389/fcvm.2022.933054. eCollection 2022.
10
Prediction of 10-year Atherosclerotic Cardiovascular Disease Risk among Adults Aged 40-79 Years in China: a Nationally Representative Survey.中国40-79岁成年人10年动脉粥样硬化性心血管疾病风险预测:一项全国代表性调查。
Biomed Environ Sci. 2017 Apr;30(4):244-254. doi: 10.3967/bes2017.034.

引用本文的文献

1
Absolute risk-based versus individualized benefit approaches for determining statin eligibility in primary prevention of cardiovascular diseases in Chinese populations: A modeling study.基于绝对风险与个体化获益方法在中国人群心血管疾病一级预防中确定他汀类药物适用资格的建模研究
PLoS Med. 2025 Jul 22;22(7):e1004556. doi: 10.1371/journal.pmed.1004556. eCollection 2025 Jul.
2
Evaluation of the ultrasonic arterial measurement and analysis system for predicting 10-year atherosclerotic cardiovascular disease risk in patients with type 2 diabetes.评估用于预测2型糖尿病患者10年动脉粥样硬化性心血管疾病风险的超声动脉测量与分析系统。
Quant Imaging Med Surg. 2025 Jun 6;15(6):4921-4934. doi: 10.21037/qims-24-1620. Epub 2025 Jun 3.
3

本文引用的文献

1
Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.高血压患病率与控制情况的全球差异:来自90个国家基于人群研究的系统分析
Circulation. 2016 Aug 9;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912.
2
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲临床实践心血管疾病预防指南:欧洲心脏病学会和其他学会关于临床实践心血管疾病预防的第六联合工作组(由10个学会的代表和特邀专家组成)由欧洲心血管预防与康复协会(EACPR)特别贡献制定。
Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.
Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis.
中国他汀类药物治疗起始阈值用于动脉粥样硬化预防的卫生经济学评估:一项成本效益分析
Int J Equity Health. 2025 Jan 24;24(1):31. doi: 10.1186/s12939-025-02391-9.
4
The effect of blood flow-restrictive resistance training on the risk of atherosclerotic cardiovascular disease in middle-aged patients with type 2 diabetes: a randomized controlled trial.血流限制阻力训练对 2 型糖尿病中年患者发生动脉粥样硬化性心血管疾病风险的影响:一项随机对照试验。
Front Endocrinol (Lausanne). 2024 Oct 1;15:1482985. doi: 10.3389/fendo.2024.1482985. eCollection 2024.
5
Effect of Sarcopenia on 10-Year Risk of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.肌肉减少症对2型糖尿病患者10年动脉粥样硬化性心血管疾病风险的影响。
Diabetes Metab Syndr Obes. 2024 Apr 9;17:1621-1634. doi: 10.2147/DMSO.S450225. eCollection 2024.
6
Ceramide d18:1/24:1 as a potential biomarker to differentiate obesity subtypes with unfavorable health outcomes.神经酰胺 d18:1/24:1 可作为区分不良健康结局肥胖亚型的潜在生物标志物。
Lipids Health Dis. 2023 Oct 4;22(1):166. doi: 10.1186/s12944-023-01921-0.
7
Age at diagnosis, diabetes duration and the risk of cardiovascular disease in patients with diabetes mellitus: a cross-sectional study.发病年龄、糖尿病病程与糖尿病患者心血管疾病风险:一项横断面研究。
Front Endocrinol (Lausanne). 2023 May 8;14:1131395. doi: 10.3389/fendo.2023.1131395. eCollection 2023.
8
Serum creatinine levels, traditional cardiovascular risk factors and 10-year cardiovascular risk in Chinese patients with hypertension.血清肌酐水平、传统心血管危险因素与中国高血压患者的 10 年心血管风险
Front Endocrinol (Lausanne). 2023 Mar 16;14:1140093. doi: 10.3389/fendo.2023.1140093. eCollection 2023.
9
Integrating polygenic and clinical risks to improve stroke risk stratification in prospective Chinese cohorts.整合多基因风险和临床风险以提高前瞻性中国队列中风风险分层。
Sci China Life Sci. 2023 Jul;66(7):1626-1635. doi: 10.1007/s11427-022-2280-3. Epub 2023 Mar 3.
10
A randomized controlled trial of Baduanjin exercise to reduce the risk of atherosclerotic cardiovascular disease in patients with prediabetes.八段锦运动降低糖尿病前期患者动脉粥样硬化性心血管疾病风险的随机对照试验。
Sci Rep. 2022 Nov 11;12(1):19338. doi: 10.1038/s41598-022-22896-5.
3
Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013.1990-2013 年中国 240 种疾病的特定病因死亡率:2013 年全球疾病负担研究的国家间系统分析。
Lancet. 2016 Jan 16;387(10015):251-72. doi: 10.1016/S0140-6736(15)00551-6. Epub 2015 Oct 26.
4
Prevalence and Secular Trends in Obesity Among Chinese Adults, 1991-2011.1991 - 2011年中国成年人肥胖的患病率及长期趋势
Am J Prev Med. 2015 Nov;49(5):661-669. doi: 10.1016/j.amepre.2015.05.005. Epub 2015 Aug 12.
5
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会心血管风险评估指南:美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. doi: 10.1161/01.cir.0000437741.48606.98. Epub 2013 Nov 12.
6
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南:美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
7
Prevalence and control of diabetes in Chinese adults.中国成年人糖尿病的患病率和控制情况。
JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.
8
Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010.中国 1990-2010 年的快速健康转型:2010 年全球疾病负担研究的发现。
Lancet. 2013 Jun 8;381(9882):1987-2015. doi: 10.1016/S0140-6736(13)61097-1.
9
[Chinese guidelines for prevention of cardiovascular diseases].[中国心血管疾病预防指南]
Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jan;39(1):3-22.
10
Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults.中国成年人致死性和非致死性缺血性心血管疾病的10年风险评估
Circulation. 2006 Nov 21;114(21):2217-25. doi: 10.1161/CIRCULATIONAHA.105.607499. Epub 2006 Nov 6.